{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:11:22Z","timestamp":1793257882510,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Prophylactic administration of antibiotics before skin incision is an important component in the prevention of periprosthetic joint infection in arthroplasty surgery. For antibiotics to be effective, the local tissue concentration (LTC) must exceed the minimum inhibitory concentration of typical infecting organisms; however, the LTC of cefazolin during arthroplasty is poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the systemic concentration of cefazolin in serum with the LTC in fat, synovium, and bone during primary total knee arthroplasty (TKA) while assessing the effect of tourniquet inflation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This prospective randomized clinical trial was conducted from March 1, 2022, to June 30, 2023, in patients undergoing TKA at a single academic center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Total knee arthroplasty with or without a limb tourniquet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Systemic blood and local tissues from the surgical site (fat, synovium, and bone) were harvested at regular intervals during the surgery. The primary outcome was the LTC of cefazolin, quantified using the liquid chromatography\u2013tandem mass spectrometry technique.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 59 patients were included in the study, with 29 in the tourniquet group (mean [SD] age, 69.3 [9.6] years; 23 [79.3%] female) and 30 in the no tourniquet group (mean [SD] age, 69.9 [9.7] years; 21 [70.0%] female). In patients undergoing TKA without a tourniquet, the mean concentration of cefazolin in serum was 71.9 \u03bcg\/mL (95% CI, 66.4-77.5 \u03bcg\/mL), whereas the mean LTCs were 13.9 \u03bcg\/g (95% CI, 12.1-15.7 \u03bcg\/g) in fat, 27.7 \u03bcg\/g (95% CI, 24.3-31.0 \u03bcg\/g) in synovium, and 17.7 \u03bcg\/g (95% CI, 14.8-20.5 \u03bcg\/g) in bone. For patients undergoing TKA with a tourniquet, the mean concentration of cefazolin in serum was 72.0 \u03bcg\/mL (95% CI, 66.3-77.7 \u03bcg\/mL), and the mean LTCs were 9.9 \u03bcg\/g (95% CI, 8.7-11.1 \u03bcg\/g) in fat, 21.8 \u03bcg\/g (95% CI, 18.7-25.0 \u03bcg\/g) in synovium, and 13.0 \u03bcg\/g (95% CI, 10.8-15.2 \u03bcg\/g) in bone. The use of a tourniquet resulted in significantly lower mean LTCs by 60 minutes after cefazolin infusion (10.8 \u03bcg\/g [95% CI, 9.1-12.4 \u03bcg\/g] vs 16.9 \u03bcg\/g [95% CI, 14.1-19.6 \u03bcg\/g], <jats:italic>P<\/jats:italic>\u2009=\u2009.001 in fat; 18.9 \u03bcg\/g [95% CI, 14.1-23.6 \u03bcg\/g] vs 25.8 \u03bcg\/g [95% CI, 21.4-30.3 \u03bcg\/g], <jats:italic>P<\/jats:italic>\u2009=\u2009.03 in synovium; and 11.8 \u03bcg\/g [95% CI, 9.3-14.2 \u03bcg\/g] vs 19.4 \u03bcg\/g [95% CI, 14.5-24.4 \u03bcg\/g], <jats:italic>P<\/jats:italic>\u2009=\u2009.007 in bone).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this randomized clinical trial, the concentration of cefazolin was lower in local tissues (fat, synovium, and bone) than in systemic blood, and the use of a limb tourniquet further significantly reduced these concentrations. Although the current prophylactic dosing regimen for cefazolin provides sufficient serum concentrations, the levels in the periarticular tissue during TKA may be insufficient to prevent periprosthetic joint infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05604157\">NCT05604157<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.29702","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:41:57Z","timestamp":1724427717000},"page":"e2429702","source":"Crossref","is-referenced-by-count":6,"title":["Tourniquet Use and Local Tissue Concentrations of Cefazolin During Total Knee Arthroplasty"],"prefix":"10.1001","volume":"7","author":[{"given":"Julien","family":"Montreuil","sequence":"first","affiliation":[{"name":"Division of Orthopaedic Surgery, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tanzer","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Surgery, McGill University, Montreal, Quebec, Canada"},{"name":"Jo Miller Orthopaedic Research Laboratory, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Research Institute, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Rajda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daina","family":"Avizonis","sequence":"additional","affiliation":[{"name":"Metabolomics Innovation Resource, Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hart","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Surgery, McGill University, Montreal, Quebec, Canada"},{"name":"Jo Miller Orthopaedic Research Laboratory, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"issue":"1","key":"zoi240905r1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jamcollsurg.2016.10.029","article-title":"American College of Surgeons and Surgical Infection Society: surgical site infection guidelines, 2016 update.","volume":"224","author":"Ban","year":"2017","journal-title":"J Am Coll Surg"},{"issue":"8","key":"zoi240905r3","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.5435\/JAAOS-D-15-00017","article-title":"Principles of antibiotic prophylaxis in total joint arthroplasty: current concepts.","volume":"23","author":"Bosco","year":"2015","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"zoi240905r4","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.arth.2020.12.005","article-title":"Projected economic burden of periprosthetic joint infection of the hip and knee in the United States.","volume":"36","author":"Premkumar","year":"2021","journal-title":"J Arthroplasty"},{"issue":"2","key":"zoi240905r5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection.","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"zoi240905r6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2106\/00004623-200707000-00027","article-title":"Prevention of perioperative infection.","volume":"89","author":"Fletcher","year":"2007","journal-title":"J Bone Joint Surg Am"},{"issue":"12","key":"zoi240905r7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1086\/421095","article-title":"Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.","volume":"38","author":"Bratzler","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi240905r8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamasurg.2013.134","article-title":"Timing of surgical antibiotic prophylaxis and the risk of surgical site infection.","volume":"148","author":"Hawn","year":"2013","journal-title":"JAMA Surg"},{"issue":"4","key":"zoi240905r9","doi-asserted-by":"publisher","first-page":"E415","DOI":"10.1503\/cjs.019621","article-title":"Local tissue concentrations of cefazolin during total joint arthroplasty: a systematic review.","volume":"66","author":"Mannarino","year":"2023","journal-title":"Can J Surg"},{"key":"zoi240905r10","first-page":"161","article-title":"The effective period of preventive antibiotic action in experimental incisions and dermal lesions.","volume":"50","author":"Burke","year":"1961","journal-title":"Surgery"},{"issue":"12","key":"zoi240905r11","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1007\/s11999-011-2111-8","article-title":"Are bone and serum cefazolin concentrations adequate for antimicrobial prophylaxis?","volume":"469","author":"Yamada","year":"2011","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"zoi240905r12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11999-012-2469-2","article-title":"Higher cefazolin concentrations with intraosseous regional prophylaxis in TKA.","volume":"471","author":"Young","year":"2013","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"zoi240905r13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.mehy.2014.03.020","article-title":"Cefazolin should be administered maximum 30 min before incision in total knee arthroplasty when tourniquet is used.","volume":"82","author":"Bicanic","year":"2014","journal-title":"Med Hypotheses"},{"issue":"11","key":"zoi240905r14","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1128\/AAC.01348-13","article-title":"Tissue pharmacokinetics of cefazolin in patients with lower limb infections.","volume":"57","author":"Bhalodi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"zoi240905r15","doi-asserted-by":"publisher","DOI":"10.1177\/10225536231191607","article-title":"Tourniquet use benefits to reduce intraoperative blood loss in patients receiving total knee arthroplasty for osteoarthritis: an updated meta-analysis with trial sequential analysis.","author":"Xu","journal-title":"J Orthop Surg (Hong Kong)"},{"issue":"1","key":"zoi240905r16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40634-022-00485-9","article-title":"Tourniquet use in total knee arthroplasty and the risk of infection: a meta-analysis of randomised controlled trials.","volume":"9","author":"Magan","year":"2022","journal-title":"J Exp Orthop"},{"key":"zoi240905r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115566","article-title":"A novel method for quantification of cefazolin local tissue concentration in blood, fat, synovium, and bone marrow using liquid chromatography\u2013mass spectrometry.","volume":"234","author":"Russo","year":"2023","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"zoi240905r18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/FTD.0000000000000555","article-title":"Simultaneous determination of cefalexin, cefazolin, flucloxacillin, and probenecid by liquid chromatography-tandem mass spectrometry for total and unbound concentrations in human plasma.","volume":"40","author":"Zhang","year":"2018","journal-title":"Ther Drug Monit"},{"key":"zoi240905r19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review.","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"zoi240905r20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11695-018-3497-0","article-title":"Prophylactic cefazolin dosing and surgical site infections: does the dose matter in obese patients?","volume":"29","author":"Hussain","year":"2019","journal-title":"Obes Surg"},{"issue":"6","key":"zoi240905r21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/17453674.2021.1942620","article-title":"Effects of tourniquet inflation on peri- and postoperative cefuroxime concentrations in bone and tissue.","volume":"92","author":"Hanberg","year":"2021","journal-title":"Acta Orthop"},{"key":"zoi240905r22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.900551","article-title":"An overview of the protein binding of cephalosporins in human body fluids: a systematic review.","volume":"13","author":"Jongmans","year":"2022","journal-title":"Front Pharmacol"},{"key":"zoi240905r2","unstructured":"Canadian Institute for Health Information. Hip and knee replacements in Canada, 2017-2018: Canadian Joint Replacement Registry annual report. Accessed July 8, 2024. https:\/\/secure.cihi.ca\/free_products\/cjrr-annual-report-2019-en-web.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822773\/montreuil_2024_oi_240905_1723814028.71009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:42:04Z","timestamp":1724427724000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822773"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.29702","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}